KLOW Peptide Blend (KPV, GHK-Cu, BPC-157, TB-500): Evidence and Legal Status

KLOW is a four-peptide blend sold online, usually as an 80 mg vial of GHK-Cu, BPC-157, TB-500 and KPV. Sellers market it for tissue repair, skin and gut inflammation. No study of the blend itself has been published, and each ingredient has little or no human data behind it^[4][5]. The regulatory answer is also clearer than most people expect. Under a draft HHS enforcement policy announced October 28, 2026, HHS says it does not intend to take action against 503A pharmacies that compound six listed peptides under ten conditions, and only as single-ingredient products^[1]. The policy is not final and is not binding on HHS or the public, and comments are open until November 13, 2026^[12]. A premixed blend does not qualify, and GHK-Cu is not on the list at all. This article covers what is in KLOW, what the evidence shows for each part, and why the new policy leaves KLOW where it was.

What is KLOW?

KLOW is a trade name used by online peptide sellers, not a drug name or a pharmacy product. The seller listings we reviewed in October 2026 all describe the same four peptides in one freeze-dried vial, and the listing that gives a breakdown lists 50 mg GHK-Cu plus 10 mg each of BPC-157, TB-500 and KPV, for 80 mg in total^[2]. Every listing we read carried a “research use only” or “not for human consumption” disclaimer. Reconstitution volumes in seller guides varied, so the amount of each peptide per injection differs from one guide to the next.

Does KLOW work? What the evidence shows

There is no published study of KLOW, or of any product that combines these four peptides. A PubMed search for studies that test GHK-Cu, BPC-157, TB-500 and KPV together returns nothing; the papers that mention them side by side are reviews that discuss each peptide separately^[8][9]. So any claim that the blend works better than its parts, or that the four act together, has no data behind it. What exists is evidence on the individual peptides, and it is thin.

BPC-157

A 2026 systematic review found three human studies of BPC-157, with 30 participants in total: a retrospective series of knee injections (16 people), a retrospective pilot of bladder instillations for interstitial cystitis (12 people), and a two-person intravenous safety pilot. All three were judged to be of poor methodological quality, and the reviewers rated the overall certainty of evidence as very low^[4]. A 2026 pharmaceutical review reached a similar view, noting that BPC-157 has no approved formulation, no validated dosing regimen and no completed Phase II trial^[3]. The animal literature is large, but rat data do not establish that the peptide helps people. Our BPC-157 safety review covers the risk side.

TB-500

TB-500 is often described as “thymosin beta-4,” but it is a different molecule: a seven-amino-acid fragment. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons noted that TB-500 is frequently conflated with full-length thymosin beta-4 without any validated biologic or clinical equivalence, and that direct musculoskeletal evidence for thymosin beta-4 is limited to cell and rodent studies^[5]. The human data people cite for “TB-500” usually belong to the parent protein, not the fragment in the vial. Our page on TB-500 side effects and safety covers that mix-up in detail.

GHK-Cu

GHK-Cu has the longest track record of the four, but almost all of the human experience is topical. A 2015 review by the peptide’s original researcher and colleagues describes cosmetic studies in which GHK-Cu creams improved skin firmness, fine lines and photodamage, alongside wound-healing results in animals^[6]. That is a skin-care evidence base. It does not tell us what a 50 mg dose of GHK-Cu does when injected under the skin, and no published human trial has tested that. See our reviews of GHK-Cu for skin and hair and the copper peptide evidence.

KPV

KPV’s best-known study is a 2008 Gastroenterology paper in human cell lines and mice. KPV entered intestinal and immune cells through the PepT1 transporter, reduced inflammatory signaling, and, given in drinking water, reduced the severity of two chemically induced forms of colitis in mice^[7]. The authors concluded it “might be” a new therapeutic agent for inflammatory bowel disease. We found no published human trial. Note that the mouse work used oral dosing, while KLOW is sold for injection. More detail is in our KPV evidence review, and our comparison of KPV by route sets the oral, topical and injected forms side by side.

Is KLOW legal after the draft HHS peptide policy?

On October 28, 2026, HHS announced a draft policy saying it does not intend to take enforcement action against a State-licensed pharmacy, Federal facility or licensed physician that compounds one of six peptides (BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500) when ten conditions are all met^[1]. This is non-binding enforcement discretion while FDA works on the 503A bulks list by rulemaking. It is not FDA approval: the policy itself states that compounded drugs are not FDA-approved and that FDA does not review their safety, effectiveness or quality^[1]. KLOW fails the conditions in three separate ways:

1. It contains more than one active ingredient. Condition 7 requires that the compounded product contain “only a single Active Pharmaceutical Ingredient (API)” from Appendix A. HHS gives the reason: with one ingredient per product, adverse events and outcomes can be attributed to a specific substance^[1]. A four-peptide vial cannot meet that condition, and neither can the two-peptide BPC-157 and TB-500 “Wolverine” blends covered in our stack review.
2. Most of the vial is a peptide the policy does not list. Appendix A names six peptides, and GHK-Cu is not one of them^[1]. In a typical 80 mg KLOW vial, about 50 mg is GHK-Cu^[2].
3. The KPV route is wrong. Appendix B limits KPV acetate to topical and oral dosage forms^[1]. KLOW is sold as an injectable vial, so even a single-ingredient KPV injection would sit outside the policy.

Separately, BPC-157 acetate is covered for subcutaneous, intramuscular, oral and topical forms, and TB-500 acetate for subcutaneous or intramuscular injection, each as a single-ingredient product made from a bulk substance with a full certificate of analysis and dispensed on a patient-specific prescription^[1]. That is the compounded route HHS says it will not take enforcement action against. A premixed blend is not part of it, even when a clinician prescribes it. When we checked the telehealth providers in our catalog on October 30, 2026, several sold multi-peptide blends on a prescription basis, including a four-peptide injectable blend containing KPV. A prescription does not bring a blend inside the policy.

What about research-use-only KLOW?

HHS framed the policy as a way to discourage widespread use of research-use-only peptides from foreign manufacturers by offering a more controlled alternative^[1]. It does not make research-chemical sales lawful. FDA has issued warning letters to online peptide sellers stating that, despite “for research use only” labels, evidence from the sellers’ own websites showed the products were intended as drugs for human use^[10]. You can browse those actions in our FDA warning letter tracker. For the legal tiers in general, see Are peptides legal?

KLOW dosage: why there is no answer

Searches for “KLOW peptide dosage” and “KLOW dose per day” are common, but there is no established dose for the blend or for any of its parts. No dose-finding study exists for KLOW, and the HHS policy sets no dose for the peptides it covers^[1][3]. Seller “protocols” are not clinical guidance; they also disagree with each other on how much water to add, which changes the amount in every syringe^[2]. Because the ratio is fixed in the vial, any attempt to dose one ingredient also doses the other three. Our BPC-157 dosage page explains why even the single peptide has no evidence-based dose.

What a covered alternative looks like

If you and a clinician decide one of these peptides is worth trying, the draft policy points to a narrower route: a single peptide from Appendix A, by an allowed route, compounded by a State-licensed 503A pharmacy for you by name, with the label line “This is a compounded drug product. Not for resale.”^[1] Our guide to getting BPC-157 online with a prescription walks through the prescription, the pharmacy checks and the red flags. Our BPC-157 provider page and TB-500 provider page list every seller we confirmed sells that peptide as a single-ingredient product, show the form each one sells, and label any form the policy does not cover; blends such as KLOW are left off. A listing does not confirm that the pharmacy meets the policy’s other conditions, so use the checklist in that guide yourself: a certificate of analysis, a single active ingredient, the label line, an allowed route, a 510(k)-cleared syringe as the only device, and a State-licensed 503A pharmacy. Supply is likely to be limited at first: the president of a Florida compounding company told NPR he did not think all the 503A pharmacies in the country could meet demand^[11].

GHK-Cu is widely sold in topical cosmetic products, which is where its human data come from^[6]. KPV under the policy is a topical or oral product only^[1]. For the general risks of combining peptides, see our peptide stacking safety review; for the policy itself, see our news report.

Bottom line

KLOW combines four peptides that each lack controlled human evidence, and the combination itself has never been studied^[4][5]. The draft HHS policy does not cover it: the policy requires a single active ingredient, does not list GHK-Cu, and does not allow injected KPV^[1]. A KLOW vial bought online is a research-use-only product, which is the supply channel the policy was written to steer people away from.